Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Insmed reported Q3 2026 total revenues of $524.4 million, up 268% year-over-year, driven by BRINSUPRI's U.S. launch, which generated $400.1 million — 29% sequential growth. ARIKAYCE added $124.4 million, up 9% YoY, and the company raised full-year 2026 guidance for both products: BRINSUPRI to $1.35B-$1.4B and ARIKAYCE to $460M-$470M. The net loss narrowed sharply to $100.3 million ($0.46/share) from $370.0 million a year ago, with $1.1 billion in cash and marketable securities on hand.
Key figures
- Revenue
- 524400000
- Guidance
- FY2026 BRINSUPRI revenue raised to $1.35B-$1.4B (from $1.25B-$1.4B); ARIKAYCE raised to $460M-$470M (from $450M-$470M)
- Revenue Yoy
- 268%
- Net loss
- 100319000
- Rd expense
- 269963000
- Sga expense
- 253029000
- Arikayce revenue
- 124400000
- Brinsupri revenue
- 400100000
- Arikayce yoy growth
- 9%
- Brinsupri qoq growth
- 29%
- Palme ild enrollment
- >35% of patients enrolled, completion expected 1H 2028
- Cash and marketable securities
- $1.1 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.